These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
353 related articles for article (PubMed ID: 33332766)
1. Inflammation initiates a vicious cycle between obesity and nonalcoholic fatty liver disease. Luo Y; Lin H Immun Inflamm Dis; 2021 Mar; 9(1):59-73. PubMed ID: 33332766 [TBL] [Abstract][Full Text] [Related]
2. Recent Advances in Adipose Tissue Dysfunction and Its Role in the Pathogenesis of Non-Alcoholic Fatty Liver Disease. Wang X; Rao H; Liu F; Wei L; Li H; Wu C Cells; 2021 Nov; 10(12):. PubMed ID: 34943809 [TBL] [Abstract][Full Text] [Related]
4. NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk. Ballestri S; Nascimbeni F; Baldelli E; Marrazzo A; Romagnoli D; Lonardo A Adv Ther; 2017 Jun; 34(6):1291-1326. PubMed ID: 28526997 [TBL] [Abstract][Full Text] [Related]
5. Does adipose tissue inflammation drive the development of non-alcoholic fatty liver disease in obesity? Cordeiro A; Costa R; Andrade N; Silva C; Canabrava N; Pena MJ; Rodrigues I; Andrade S; Ramalho A Clin Res Hepatol Gastroenterol; 2020 Sep; 44(4):394-402. PubMed ID: 32044284 [TBL] [Abstract][Full Text] [Related]
6. New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis. Pydyn N; Miękus K; Jura J; Kotlinowski J Pharmacol Rep; 2020 Feb; 72(1):1-12. PubMed ID: 32016853 [TBL] [Abstract][Full Text] [Related]
7. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Polyzos SA; Kountouras J; Mantzoros CS Metabolism; 2019 Mar; 92():82-97. PubMed ID: 30502373 [TBL] [Abstract][Full Text] [Related]
8. Association of Adipose Tissue Inflammation With Histologic Severity of Nonalcoholic Fatty Liver Disease. du Plessis J; van Pelt J; Korf H; Mathieu C; van der Schueren B; Lannoo M; Oyen T; Topal B; Fetter G; Nayler S; van der Merwe T; Windmolders P; Van Gaal L; Verrijken A; Hubens G; Gericke M; Cassiman D; Francque S; Nevens F; van der Merwe S Gastroenterology; 2015 Sep; 149(3):635-48.e14. PubMed ID: 26028579 [TBL] [Abstract][Full Text] [Related]
9. Nonalcoholic fatty liver disease in the over-60s: Impact of sarcopenia and obesity. Wijarnpreecha K; Panjawatanan P; Aby E; Ahmed A; Kim D Maturitas; 2019 Jun; 124():48-54. PubMed ID: 31097179 [TBL] [Abstract][Full Text] [Related]
10. Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. Francque S; Szabo G; Abdelmalek MF; Byrne CD; Cusi K; Dufour JF; Roden M; Sacks F; Tacke F Nat Rev Gastroenterol Hepatol; 2021 Jan; 18(1):24-39. PubMed ID: 33093663 [TBL] [Abstract][Full Text] [Related]
11. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question. Streba LA; Vere CC; Rogoveanu I; Streba CT World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859 [TBL] [Abstract][Full Text] [Related]
12. COVID-19 and liver injury in individuals with obesity. Lempesis IG; Karlafti E; Papalexis P; Fotakopoulos G; Tarantinos K; Lekakis V; Papadakos SP; Cholongitas E; Georgakopoulou VE World J Gastroenterol; 2023 Feb; 29(6):908-916. PubMed ID: 36844135 [TBL] [Abstract][Full Text] [Related]
13. Nonalcoholic fatty liver disease burden - Saudi Arabia and United Arab Emirates, 2017-2030. Alswat K; Aljumah AA; Sanai FM; Abaalkhail F; Alghamdi M; Al Hamoudi WK; Al Khathlan A; Al Quraishi H; Al Rifai A; Al Zaabi M; Babatin MA; Estes C; Hashim A; Razavi H Saudi J Gastroenterol; 2018; 24(4):211-219. PubMed ID: 29956688 [TBL] [Abstract][Full Text] [Related]
14. Obesity, Nonalcoholic Fatty Liver Disease and Adipocytokines Network in Promotion of Cancer. Divella R; Mazzocca A; Daniele A; Sabbà C; Paradiso A Int J Biol Sci; 2019; 15(3):610-616. PubMed ID: 30745847 [TBL] [Abstract][Full Text] [Related]